ArticleKorean journal of radiology2022
T2 Mapping with and without Fat-Suppression to Predict Treatment Response to Intravenous Glucocorticoid Therapy for Thyroid-Associated Ophthalmopathy.
Article in Korean journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease.European thyroid journal · 2024Pooled it
- Current insights of applying MRI in Graves' ophthalmopathy.Frontiers in endocrinology · 2022Pooled it
- MRI-based automated segmentation and multiparametric quantification for assessing orbital soft tissue involvement in thyroid eye disease.European radiology · 2026Article
- Habitat imaging based on water-fat separation for interpreting extraocular muscle heterogeneity in thyroid eye disease.European thyroid journal · 2026Article
- Quantitative Chemical Exchange Saturation Transfer MRI for Diagnosing Thyroid-Associated Ophthalmopathy Activity: A Prospective Feasibility Study.Korean journal of radiology · 2026Article
- Quantitative intravoxel incoherent motion diffusion-weighted imaging histogram profiling identifies diffusion biomarkers for active thyroid-associated ophthalmopathy.BMC medical imaging · 2026Article
- Rapid multiparametric quantitative MRI for predicting the activity of thyroid-associated ophthalmopathy: combination with clinical characteristics.European radiology · 2025Article
- Article
- Radiomics analysis based on T2-weighed imaging and T2 mapping for staging endometrial fibrosis.Scientific reports · 2025Article
- Fat-suppression T2 relaxation time and water fraction predict response to intravenous glucocorticoid therapy for thyroid-associated ophthalmopathy.European radiology · 2025Article
- Multimodal MRI radiomics-clinical fusion model predicts intravenous glucocorticoid response in thyroid eye disease.Frontiers in endocrinology · 2025Article
- Application progress of magnetic resonance imaging in thyroid associated ophthalmopathy.Frontiers in endocrinology · 2025Review
- Assessment of disease activity in Graves' orbitopathy.Frontiers in ophthalmology · 2025Review
- Predicting glucocorticoid effectiveness in thyroid eye disease: combined value from serological lipid metabolism and an orbital MRI parameter.European thyroid journal · 2024Article
- Application of quantitative orbital analysis to assess the activity of Graves' ophthalmopathy.American journal of nuclear medicine and molecular imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the performance of baseline clinical characteristics and pretherapeutic histogram parameters derived from T2 mapping of the extraocular muscles (EOMs) in the prediction of treatment response to intravenous glucocorticoid (IVGC) therapy for active and moderate-to-severe thyroid-associated ophthalmopathy (TAO) and to investigate the effect of fat-suppression (FS) in T2 mapping in this prediction. MATERIALS AND
methodsA total of 79 patients clinically diagnosed with active, moderate-to-severe TAO (47 female, 32 male; mean age ± standard deviation, 46.1 ± 10 years), including 43 patients with a total of 86 orbits in the responsive group and 36 patients with a total of 72 orbits in the unresponsive group, were enrolled. Baseline clinical characteristics and pretherapeutic histogram parameters derived from T2 mapping with FS (i.e., FS T2 mapping) or without FS (i.e., conventional T2 mapping) of EOMs were compared between the two groups. Independent predictors of treatment response to IVGC were identified using multivariable analysis. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive performance of the prediction models. Differences between the models were examined using the DeLong test.
resultsCompared to the unresponsive group, the responsive group had a shorter disease duration, lower kurtosis (FS-kurtosis), lower standard deviation, larger 75th, 90th, and 95th (FS-95th) T2 relaxation times in FS mapping and lower kurtosis in conventional T2 mapping. Multivariable analysis revealed that disease duration, FS-95th percentile, and FS-kurtosis were independent predictors of treatment response. The combined model, integrating all identified predictors, had an optimized area under the ROC curve of 0.797, 88.4% sensitivity, and 62.5% specificity, which were significantly superior to those of the imaging model (
conclusionAn integrated combination of disease duration, FS-95th percentile, and FS-kurtosis was a potential predictor of treatment response to IVGC in patients with active and moderate-to-severe TAO. FS T2 mapping was superior to conventional T2 mapping in terms of prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.